New Guidelines and Evidence to Improve Management of Patients with or at High Risk of ASCVD Events


This interactive CME symposium will feature a faculty of 3 leading international experts who will address how to reduce residual risk in patients with atherosclerotic cardiovascular disease (ASCVD) beyond LDL-C lowering.  This ACPE initiative for healthcare pharmacists narrows unmet medical needs and will provide the learner with a unique series of learning experiences that promises to lead to improved clinical practice and may measurably improve health outcomes. The education addresses national educational needs and uses adult learning principles to engage the learners in interactive educational interventions. 

Registration is now open at


Pharmacist Learning Objectives

At the conclusion of this activity, learners should be better able to:

  1. Have greater clarity on implementing the new 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
  2. Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
  3. Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
  4. Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events




Presented by Medtelligence, Inc. and supported by an independent educational grant from Amarin Pharma, Inc.

Learning Level: Level 2
Track: Satellite Symposia
Session Time Slot(s): 
Saturday, March 23
6:00 PM - 9:00 PM
Grand Hyatt Seattle - Leonesa II, III
ACPE Pharmacist: JA4008162-9999-19-587-L01-P
CEUs Pharmacist: 0.2
Activity Type: